JENNIFER LANG: Open Payments
NPI 1003364795 · CHEVY CHASE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,928 in 82 payments from 17 companies in 2025. Trend: 2023 $1,287 · 2024 $1,764 · 2025 $1,928
Food & beverage: $1,928
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 22 | $496 |
| Janssen Biotech, Inc. | 7 | $166 |
| GENZYME CORPORATION | 6 | $160 |
| PFIZER INC. | 9 | $157 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $147 |
| Ardelyx, Inc. | 3 | $142 |
| Janssen Scientific Affairs, LLC | 1 | $127 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 5 | $107 |
| Phathom Pharmaceuticals, Inc. | 7 | $95 |
| Ipsen Biopharmaceuticals, Inc | 4 | $91 |
Products named: RINVOQ, TREMFYA, ENTYVIO, IBSRELA, XELJANZ, XIFAXAN, VOQUEZNA, IQIRVO.
Industry payments across MD — which companies pay providers there.
